PH26083A - 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof - Google Patents
11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof Download PDFInfo
- Publication number
- PH26083A PH26083A PH37779A PH37779A PH26083A PH 26083 A PH26083 A PH 26083A PH 37779 A PH37779 A PH 37779A PH 37779 A PH37779 A PH 37779A PH 26083 A PH26083 A PH 26083A
- Authority
- PH
- Philippines
- Prior art keywords
- dermatitis
- formula
- compound
- psoriasis
- salt form
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- JQTZATZJTOJHSQ-UHFFFAOYSA-N octacos-10-ene Chemical class CCCCCCCCCCCCCCCCCC=CCCCCCCCCC JQTZATZJTOJHSQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 22
- 201000004624 Dermatitis Diseases 0.000 claims description 15
- 230000000699 topical effect Effects 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 150000003839 salts Chemical group 0.000 claims description 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 7
- 206010015150 Erythema Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 206010014950 Eosinophilia Diseases 0.000 claims description 5
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- 206010034277 Pemphigoid Diseases 0.000 claims description 5
- 241000721454 Pemphigus Species 0.000 claims description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 206010047112 Vasculitides Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 32
- 239000000126 substance Substances 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
- 108010036949 Cyclosporine Proteins 0.000 description 9
- 229930105110 Cyclosporin A Natural products 0.000 description 8
- 229960001265 ciclosporin Drugs 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000000224 granular leucocyte Anatomy 0.000 description 6
- 239000002085 irritant Substances 0.000 description 6
- 231100000021 irritant Toxicity 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- FCFMCMQSDFZKHQ-UHFFFAOYSA-N 9-(dimethylamino)-2,3-dihydrobenzo[f]phthalazine-1,4-dione Chemical compound O=C1NNC(=O)C2=C1C1=CC(N(C)C)=CC=C1C=C2 FCFMCMQSDFZKHQ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100370282 Caenorhabditis elegans tra-4 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
- 241001448862 Croton Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000008976 Pterocarpus marsupium Species 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150045848 Tmbim6 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000019236 negative regulation of macrophage activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0295287A AT400808B (de) | 1987-11-09 | 1987-11-09 | Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln |
| DE3742805 | 1987-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26083A true PH26083A (en) | 1992-02-06 |
Family
ID=25599336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH37779A PH26083A (en) | 1987-11-09 | 1988-11-07 | 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050059694A1 (online.php) |
| EP (2) | EP0315978B1 (online.php) |
| JP (1) | JP2604834B2 (online.php) |
| KR (1) | KR0133916B1 (online.php) |
| AU (1) | AU619772B2 (online.php) |
| CH (1) | CH677448A5 (online.php) |
| CY (1) | CY1730A (online.php) |
| DK (1) | DK175235B1 (online.php) |
| GB (1) | GB2212061B (online.php) |
| HK (1) | HK8694A (online.php) |
| NL (1) | NL195077C (online.php) |
| PH (1) | PH26083A (online.php) |
| SE (2) | SE503236C2 (online.php) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| US5519049A (en) * | 1989-06-06 | 1996-05-21 | Fisons Plc | Macrolides for the treatment of reversible obstructive airways diseases |
| IE64214B1 (en) * | 1989-06-06 | 1995-07-26 | Fujisawa Pharmaceutical Co | Macrolides for the treatment of reversible obstructive airways diseases |
| IE66485B1 (en) * | 1989-07-05 | 1996-01-10 | Fujisawa Pharmaceutical Co | Aqueous liquid composition for external use |
| US5215995A (en) * | 1989-10-16 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Hair revitalizing agent |
| KR0159766B1 (ko) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
| US5208228A (en) * | 1989-11-13 | 1993-05-04 | Merck & Co., Inc. | Aminomacrolides and derivatives having immunosuppressive activity |
| GB8925797D0 (en) * | 1989-11-15 | 1990-01-04 | Fisons Plc | Compositions |
| KR0177158B1 (ko) * | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
| US5064835A (en) * | 1990-03-01 | 1991-11-12 | Merck & Co., Inc. | Hydroxymacrolide derivatives having immunosuppressive activity |
| WO1991013899A1 (en) * | 1990-03-12 | 1991-09-19 | Fujisawa Pharmaceutical Co., Ltd. | Tricyclo compounds |
| EP0455427A1 (en) * | 1990-04-30 | 1991-11-06 | Merck & Co. Inc. | Deoxymacrolide derivatives having immunosuppressive activity |
| US5190950A (en) * | 1990-06-25 | 1993-03-02 | Merck & Co., Inc. | Antagonists of immunosuppressive macrolides |
| US5342935A (en) * | 1990-06-25 | 1994-08-30 | Merck & Co., Inc. | Antagonists of immunosuppressive macrolides |
| ES2099112T3 (es) * | 1990-09-04 | 1997-05-16 | Fujisawa Pharmaceutical Co | Pomadas que contienen un compuesto triciclico. |
| GB2248184A (en) * | 1990-09-28 | 1992-04-01 | Fujisawa Pharmaceutical Co | New use of macrolide compounds for active oxygen-mediated diseases |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| US5348966A (en) * | 1990-10-24 | 1994-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds |
| PH31204A (en) * | 1990-11-02 | 1998-05-05 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
| US5147877A (en) * | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
| US5162334A (en) * | 1991-05-13 | 1992-11-10 | Merck & Co., Inc. | Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity |
| US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5250678A (en) | 1991-05-13 | 1993-10-05 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
| ZA926812B (en) | 1991-09-09 | 1993-04-28 | Merck & Co Inc | O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity |
| US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
| US5247076A (en) * | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| GB9218597D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| MY110603A (en) * | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
| JPH06345646A (ja) * | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
| US5693648A (en) * | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
| NZ331824A (en) | 1994-10-26 | 2000-01-28 | Novartis Ag | use of an unsaturated fatty alcohol to stabilise a macrolide in a pharmaceutical composition |
| WO1999055332A1 (en) * | 1998-04-27 | 1999-11-04 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| EP1603560A1 (en) * | 2003-02-06 | 2005-12-14 | Cipla Ltd. | Topical immunotherapy and compositions for use therein |
| US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| JP5135441B2 (ja) * | 2008-10-08 | 2013-02-06 | 高田製薬株式会社 | タクロリムス外用剤 |
| EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| CN106074367A (zh) * | 2016-07-20 | 2016-11-09 | 中山大学中山眼科中心 | 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4139563A (en) * | 1977-07-01 | 1979-02-13 | Merrell Toraude Et Compagnie | α-ACETYLENIC DERIVATIVES OF AMINES |
| EP0012866B1 (en) * | 1978-12-21 | 1983-01-19 | Gruppo Lepetit S.P.A. | New 3h-naphtho(1,2-d)imidazoles, processes for preparing them, compounds for use as antiinflammatory and antimicrobial agents and compositions for that use containing them |
| US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| US4556654A (en) * | 1983-06-28 | 1985-12-03 | Warner-Lambert Company | Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones |
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| CA1272953A (en) * | 1984-10-08 | 1990-08-21 | Yuji Makino | Pharmaceutical composition for external use containing active-type vitamin d.sub.3 |
-
1988
- 1988-11-07 CH CH4131/88A patent/CH677448A5/de not_active IP Right Cessation
- 1988-11-07 DK DK198806203A patent/DK175235B1/da not_active IP Right Cessation
- 1988-11-07 PH PH37779A patent/PH26083A/en unknown
- 1988-11-07 GB GB8826066A patent/GB2212061B/en not_active Expired - Lifetime
- 1988-11-08 SE SE8804036A patent/SE503236C2/sv unknown
- 1988-11-08 KR KR1019880014649A patent/KR0133916B1/ko not_active Expired - Lifetime
- 1988-11-08 JP JP63283524A patent/JP2604834B2/ja not_active Expired - Lifetime
- 1988-11-08 NL NL8802734A patent/NL195077C/nl not_active IP Right Cessation
- 1988-11-08 AU AU24902/88A patent/AU619772B2/en not_active Expired
- 1988-11-09 EP EP88118669A patent/EP0315978B1/en not_active Expired - Lifetime
- 1988-11-09 EP EP93120261A patent/EP0596541B1/en not_active Expired - Lifetime
-
1994
- 1994-01-21 HK HK86/94A patent/HK8694A/xx not_active IP Right Cessation
- 1994-05-06 CY CY173094A patent/CY1730A/en unknown
- 1994-07-22 SE SE9402558A patent/SE519137C2/sv unknown
-
2004
- 2004-09-24 US US10/948,188 patent/US20050059694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NL195077C (nl) | 2003-07-23 |
| GB2212061B (en) | 1991-08-28 |
| EP0315978B1 (en) | 1994-10-26 |
| KR0133916B1 (ko) | 1998-04-22 |
| HK8694A (en) | 1994-02-04 |
| DK620388D0 (da) | 1988-11-07 |
| DK175235B1 (da) | 2004-07-19 |
| DK620388A (da) | 1989-05-10 |
| NL8802734A (nl) | 1989-06-01 |
| CY1730A (en) | 1994-05-06 |
| US20050059694A1 (en) | 2005-03-17 |
| SE9402558D0 (sv) | 1994-07-22 |
| SE519137C2 (sv) | 2003-01-21 |
| SE8804036L (sv) | 1989-05-10 |
| AU2490288A (en) | 1989-05-11 |
| JP2604834B2 (ja) | 1997-04-30 |
| EP0315978A3 (en) | 1990-06-13 |
| CH677448A5 (online.php) | 1991-05-31 |
| EP0596541B1 (en) | 2000-03-15 |
| AU619772B2 (en) | 1992-02-06 |
| EP0315978A2 (en) | 1989-05-17 |
| GB8826066D0 (en) | 1988-12-14 |
| GB2212061A (en) | 1989-07-19 |
| EP0596541A1 (en) | 1994-05-11 |
| SE503236C2 (sv) | 1996-04-22 |
| JPH01157913A (ja) | 1989-06-21 |
| SE8804036D0 (sv) | 1988-11-08 |
| KR890007736A (ko) | 1989-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0315978B1 (en) | New use of 11,28-dioxa-4-azatricyclo [22.3.1.0 4,9]octacos-18-ene derivatives and pharmaceutical compositions containing them | |
| US4914197A (en) | Novel phosphoric diesters | |
| US7629352B2 (en) | Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/smoothened signaling | |
| JP2848827B2 (ja) | フラボノイドとりん脂質との複合化合物，その製法並びに該複合化合物を含有する医薬及び化粧品組成物 | |
| KR19980069961A (ko) | 항문직장 및 결장 질병의 제어 및 치료를 위한 신규 약제학적조성물 및 그 제조방법 | |
| KR101932668B1 (ko) | 쉬나무 추출물을 유효성분으로 하는 창상 치유용 약학 조성물 | |
| WO2005082860A1 (en) | Tetracyclines and their use as calpain inhibitors | |
| Abdallah et al. | Topical delivery of quercetin loaded transfersomes for wound treatment: in vitro and in vivo evaluation | |
| WO2014098516A1 (ko) | 페길레이션된 베튤린 유도체를 포함하는 기저귀 피부염의 예방 또는 치료용 조성물 | |
| EP0269755A4 (en) | DIBENZ DERIVATIVE b, e] OXEPIN AND PHARMACEUTICAL PRODUCTS CONTAINING IT AS AN ACTIVE INGREDIENT. | |
| US5366971A (en) | Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them | |
| WO2019078463A1 (ko) | 녹차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
| PT99835B (pt) | Processo para a preparacao de esteres da castanospermina com accao antiviral | |
| US5866147A (en) | Ascorbyl-phosphoryl-cholesterol | |
| JPH0597706A (ja) | アフタ性潰瘍および他の粘膜皮膚障害の処置方法 | |
| KR101425902B1 (ko) | 하이드록삼산 유도체를 포함하는 피부 미백용 화장료 조성물 | |
| WO2008110351A2 (en) | Use of (r) and (s)-2-aryl-propionic acid derivatives as antiseptic agents | |
| KR20000035846A (ko) | 앨러지성 피부염 치료제 | |
| KR100407640B1 (ko) | 신규한 디페닐 아미드 유도체, 그의 제조방법 및 이를포함하는 약학 및 화장료 조성물 | |
| JPH11503745A (ja) | Ｈｉｖ感染症に対する２，４−ジクロロベンジルアルコール及びアミルメタクレゾール | |
| KR20260055394A (ko) | 부프레노르핀 이량체를 사용한 만성 통증 또는 위장관 장애의 치료 | |
| WO2008145759A1 (en) | New silver(i) compounds and their use in pharmaceutical compositions for the treatment, prophylaxis and prevention of infections | |
| KR20190004991A (ko) | 피부 미백용 조성물 | |
| KR20190004992A (ko) | 피부 미백용 조성물 | |
| WO2024262672A1 (ko) | 이타콘산 또는 이의 유도체를 포함하는 피부 미백용 화장료 조성물 |